Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
細分爵士製藥：15 位分析師分享他們的觀點
Providing a diverse range of perspectives from bullish to bearish, 15 analysts have published ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ) in the last three months.
在過去三個月中，有15位分析師公佈了爵士製藥（納斯達克股票代碼：JAZZ）的評級，提供了從看漲到看跌的不同視角。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表總結了他們最近的評級，展示了過去30天內不斷變化的情緒，並將其與前幾個月進行了比較。
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target is $196.6, accompanied by a high estimate of $235.00 and a low estimate of $131.00. A decline of 0.87% from the prior average price target is evident in the current average.
分析師最近對Jazz Pharmicals進行了評估，並提供了12個月的目標股價。平均目標爲196.6美元，最高估計值爲235.00美元，低估值爲131.00美元。目前的平均價格比先前的平均目標股價下降了0.87％。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The perception of Jazz Pharmaceuticals by financial...
通過分析師最近...
登入免費觀看全文
登入/註冊